Among them, 34 (29%) patients received first-line treatment, while 84 (71%) received second-line ICIs; 13.6% patients possessed high expression of PD-1/PD-L1 with tumor proportion score (TPS) ≥50%, which primarily received fist-line immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.